Jones Financial Companies’s VistaGen Therapeutics VTGN Stock Holding History

Jones Financial Companies’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$80	Hold	114	–	–	﹤0.01%	4894
2026 Q1	$65	Hold	114	–	–	﹤0.01%	4660
2025 Q4	$75	Hold	114	–	–	﹤0.01%	4326
2025 Q3	$402	Hold	114	–	–	﹤0.01%	4060
2025 Q2	$225	Buy	114 +34	+43%	+$77	﹤0.01%	3905
2025 Q1	$207	Sell	80 -200	-71%	-$566	﹤0.01%	3592
2024 Q4	$826	Buy	280 +200	+250%	+$563	﹤0.01%	3164
2024 Q3	$246	Hold	80	–	–	﹤0.01%	2932
2024 Q2	$278	Hold	80	–	–	﹤0.01%	2373
2024 Q1	$422	Hold	80	–	–	﹤0.01%	1340
2023 Q4	$411	Buy	+80	New	+$303	﹤0.01%	996

Other funds holding VTGN

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

Luminus Management Houston, Texas $146M AUM 27.83% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Jones Financial Companies's VTGN Position: Q2 2026 in Review

Jones Financial Companies held its VistaGen Therapeutics (VTGN) position steady in Q2 2026 at 114 shares worth $80. The position accounts for ﹤0.01% of the portfolio, ranked #4894.

Jones Financial Companies first reported a position in VTGN in Q4 2023 and has held it in 11 quarters since. The position peaked at $826 in Q4 2024. 48 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

Jones Financial Companies held 114 shares of VistaGen Therapeutics worth $80 as of Q2 2026.
Jones Financial Companies left its VistaGen Therapeutics share count unchanged in Q2 2026.
VistaGen Therapeutics made up ﹤0.01% of Jones Financial Companies's portfolio in Q2 2026, its #4894 holding.
Jones Financial Companies first reported a position in VistaGen Therapeutics in Q4 2023 and has held it in 11 quarters since.
Jones Financial Companies's VistaGen Therapeutics position peaked at $826 in Q4 2024.
48 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on Jones Financial Companies's 13F filing for Q2 2026, filed 14 Aug 2026.